Abstract: Tumor cell hypoxia is linked to the resistance of human solid tumors to the various anti-cancer therapies: thus, its exploitation has been considered to be a potential target for cancer treatment. Previously, we demonstrated for the first time that hypoxia inhibits apoptosis induced by tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) through blocking translocation of Bax, a pro-apoptotic protein, from the cytosol to the mitochondria. Nevertheless, the molecular mechanism coupling hypoxia to resistance for drugs, especially for anti-cancer chemotherapeutics, still remains to be elucidated. Here, we demonstrate that hypoxia attenuates camptothecin (CPT)-induced apoptosis by decreasing the protein levels of Bax, thereby leading to resistance to the drug. DNA damage after exposure to CPT resulted in an increase of p53, and a concomitant up-regulation of p21, regardless of oxygen content. Under normoxic condition, CPT induced expression of p53 and its down-stream target molecule Bax as well, in the presence of increased p21. In contrast, when preexposed to hypoxia, Bax-inducing activity of CPT was completely lost and the Bax level was even decreased, although CPT increased both p53 and p21 as observed under normoxic condition. Our data indicate that hypoxia attenuates apoptosis via Bax. Our data also suggest that hypoxia regulates tumor cell apoptosis differentially, through regulating Bax translocation or through down-regulating Bax levels, depending on death-inducing signals as shown by TRAIL-or CPT-induced apoptosis.
Introduction
Hypoxic cells are present in many human solid tumors. Hypoxia is known to lead to a negative effect on therapy such as radiation therapy and chemotherapy (Graeber et al. 1996; Dong et al. 2001; Harris 2002) . In addition, tumor hypoxia is strongly related to cancer propagation, increased metastatic potential, and poor prognosis (Teicher 1994; Vaupel et al. 2001; Shannon et al. 2003) . For these effects, hypoxia has been thought to be critical setback in cancer treatments, because it renders tumor cells more aggressive and resistant to apoptosis. Thus, it is obvious that tumor cell responses to hypoxia are critical for tumor progression as well as tumor therapy.
Most chemotherapy agents including camptothecin (CPT) destroy tumors by affecting DNA replication in cells (Rustum & Cao 1999; Trimmer & Essigmann 1999; Pommier 2006) . During DNA synthesis, CPT works as a topoisomerase I inhibitor, thereby causing doublestrand DNA damage (Liu et al. 1996; Pommier 2009 ). Studies have demonstrated that once activated by DNA damage or agent that stimulates DNA damage, cells stimulate expression of a tumor suppressor protein p53, which in turn up-regulates p21 expression to induce cell growth arrest in G1 or G2 phase until DNA repair process has been completed (Bunz et al. 1998; Hamada et al. 2009 ). If DNA damage is too severe, this potent tumor suppressor stimulates pro-apoptotic Bax to eliminate injured cells, thereby leading to apoptotic cell death (Chipuk et al. 2004) .
The mitochondrial apoptotic events are largely controlled by the Bcl-2 family of proteins, which con-sist of pro-and anti-apoptotic members. Among these Bcl-2 family members, Bax, a pro-apoptotic protein, is known to play a pivotal role in the mitochondriamediated apoptosis (LeBlanc et al. 2002; Ravi & Bedi 2002) . Studies have demonstrated that the loss of Bax in human colon cancer cells renders cells significantly resistant to some cytotoxic agents such as 5-fluorouracil (5-FU), sulindac sulfide and indomethacin, and tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL), resulting in significant inhibition of apoptosis (Zhang et al. 2000; Kohli et al. 2004) .
Our previous studies, focused on the mechanism by which hypoxia inhibits apoptosis induced by a death ligand TRAIL (Park et al. 2002; Kim et al. 2004; Han et al. 2008) , revealed that blockade of Bax translocation to the mitochondria is responsible for inhibitory effect of hypoxia on apoptosis in HCT116 colon cancer cells. A recent study also showed that hypoxia protects cancer cells from TRAIL-induced apoptosis (Nagaraj et al. 2007) . Along this line, we also examined if hypoxia has inhibitory effect on DNA damage agentinduced apoptosis in colon cancer cells. We hypothesized that hypoxia may attenuate apoptotic activity induced by CPT through the regulation of p53, p21, and/or Bax. To test our hypothesis, the expression levels of p53, p21, and Bax in CPT-treated colon cancer cells under hypoxia or normoxia were examined. Here, we show that hypoxia inhibits CPT-mediated apoptosis by down-regulating pro-apoptotic Bax protein. Our data suggest that Bax can be a potential target for chemotherapy in hypoxic malignant tumors.
Material and methods
Cell culture HCT116 human colon carcinoma cells were cultured in McCoy's 5A medium with L-glutamine containing 10% fetal bovine serum, and antibiotics (100 µg/mL gentamicin and 100 µg/mL penicillin-streptomycin).
Treatment with hypoxia HCT116 cells were exposed to hypoxia as described previously (Kim et al. 2004 ). In brief, hypoxia was applied to the cells by maintaining the cells inside an airtight chamber with inflow and outflow valves that were infused with a hypoxic gas (1% O2; 5% CO2; 94% N2) (Namiki et al. 1995) .
Measurement of cell viability HCT116 cells, plated in 12 wells, were pre-exposed to normoxic or hypoxic conditions for 24 h and further treated with CPT (1 µM), cisplatin (100 µM), and 5-FU (20 µM) for 6 h under the same conditions. Cell viability was determined by the crystal violet staining method as described (Kim et al. 2004) . Briefly, cells were stained for 10 min at room temperature with staining solution (0.5% crystal violet in 30% ethanol and 3% formaldehyde), washed four times with water, and dried. Cells were lysed with 1% sodium dodecyl sulfate solution, and measured at 550 nm. Cell viability was calculated from relative dye intensity and compared to the controls.
Western blot analysis
Whole cell lysates, prepared as described previously (Kim et al. 2004) , were resolved on a 15% sodium dodecyl sulfate gel and transferred onto the nitrocellulose membrane. Western blotting was performed using antibodies (all from Santa Cruze Biotechnology, CA) for p53 (sc-126), p21 (sc-6246), Bax (sc-493), and β-actin (sc-81178). For the quantification of Western blot data, the band densitometry analysis was performed with Image J software.
Statistical analysis
The data were expressed as mean ± S.E.M. The significance level was set at p < 0.05 for all statistical tests. Duncan's test was used to determine the significance of differences in multiple comparisons.
Results
Hypoxia attenuates CPT-induced apoptosis in human colon cancer cells Hypoxia has been considered as a crucial factor of drug resistance in tumors. Our earlier study has demonstrated for the first time that hypoxia inhibits TRAILinduced apoptosis by inhibiting Bax translocation to the mitochondria in colon cancer cells (Kim et al. 2004 ).
In agreement with our findings, recent other study has also shown that prostate epithelial cells developed resistance to TRAIL under hypoxia, as mediated via decreased Bax translocation (Walsh et al. 2009 ). As observed for TRAIL, cytotoxic activity of chemotherapeutic agents is highly attenuated under hypoxic conditions (Brown 2000) . However, fewer studies have been conducted to elucidate the mechanism by which hypoxia exhibits inhibitory effects on apoptosis induced by chemotherapeutic agents including DNA damaging agents. Thus, here, to examine how hypoxia negatively regulates apoptotic activity in response to the DNA damaging chemotherapeutics, a topoisomerase I (topo I) inhibitor CPT was used, since CPT recently resulted in completed clinical trials for treating patients with colon cancer and has been widely used in apoptosis study. First, the HCT116 human colon cancer cells, known to be relatively sensitive to CPT, were treated with high concentration of CPT (1 µM) for 6 h as a short-period exposure. Short-period and high concentration exposure is suitable for evaluating our hypothesis, because such conditions render cells more susceptible to apoptosis in HCT116 cells, allowing us to observe the inhibitory effect of hypoxia on CPT-induced apoptosis. Cell viability was determined by the crystal violet staining method as described in Materials and Methods. As shown in Figure 1 , under normoxia, CPT induced apoptotic cell death to approximately 32% within 6 h. In contrast, when pre-exposed to hypoxia for 24 h and then treated with CPT, hypoxia decreased apoptosis, indicating that hypoxia has a protective effect on CPT-induced apoptosis. The resistance response to apoptosis was about 1.3 times higher under hypoxia (86% survival) than normoxia (66% survival). To examine whether this phenomenon extends to other DNA damaging agents, such as cisplatin and Fig. 1 . Effect of hypoxia on DNA damaging agents-induced apoptosis. HCT116 cells were pre-exposed to normoxia or hypoxia for 24 h and further treated with camptothecin (CPT, 1 µM), cisplatin (100 µM), and 5-fluorouracil (5-FU, 20 µM) for an additional 6 h under the same conditions, and analyzed for cell viability using crystal violet staining method as described in "Materials and methods" section. The experiment was repeated three times. The data represent mean ± S.E.M. + p < 0.05, compared to no DNA damaging agent under normoxia; and * p < 0.05, compared to normoxia under the treatment with the indicated DNA damaging agents (CPT, cisplatin, and 5-FU), respectively.
5-FU, were also tested. As illustrated in Figure 1 , hypoxia also protected cells from apoptosis induced by both cisplatin and 5-FU, suggesting that hypoxia inhibition of DNA damaging agent-induced apoptosis is not limited to CPT. Our data indicate that hypoxia has a protective effect on apoptosis in colon cancer cells induced by DNA damaging chemotherapeutic agents. To examine whether hypoxia response coupled with CPT in HCT116 cells may be cell type-specific, MCF-7 human breast cancer cells and A549 human lung cancer cells were pre-exposed to normoxic or hypoxic conditions for 24 h, and then treated with CPT (1 µM) for 6 h for cell viability test. As shown in Figure 2 , no inhibitory effect of hypoxia on apoptosis in both MCF-7 and A549 cells in response to CPT was observed, indicating that there may be cell type-specific difference under the given experimental conditions. Hypoxia regulates CPT-induced apoptosis by downregulating Bax Next, we investigated the expression levels of key regulators involved in DNA damaging agent-induced apoptosis signaling in the HCT116 cells treated by hypoxia and/or CPT. Since up-regulated expression of p53 and its down-stream target p21 was a common characteristic of apoptosis induced by DNA damaging agent, it can be possibly assumed that the expression levels of p53 and p21, a mediator of p53-induced cell growth arrest, may be influenced by hypoxia for the attenuation of apoptosis. We first examined the levels of p53 and p21 in HCT116 cells treated with hypoxia and/or CPT. As shown in Figure 3A , Western blot analysis exhibited that DNA damage after exposure to CPT resulted in a substantial increase of p53, and a subsequent Fig. 2 . Inhibitory effect of hypoxia on CPT-induced apoptosis in HCT116 colon cancer, MCF-7 breast cancer, and A549 lung cancer cells. The cells were exposed to normoxia or hypoxia. After 24 h, the cells were coincubated with 1 µM CPT for an additional 6 h. Cell viability was determined using crystal violet staining method. The experiment was repeated three times. The data represent mean ± S.E.M. * p < 0.05, compared to normoxia in the given cancer cell lines (HCT116, MCF-7, and A549), respectively.
up-regulation of p21, regardless of oxygen content. Our findings suggest that at least p53 and p21 proteins are not responsible for the inhibitory effect of hypoxia on CPT-induced apoptosis in our experimental conditions.
It is known that HCT116 cells treated with CPT undergo p53-dependent apoptosis. In normal cells, p53 is expressed at extremely low levels. However, upon exposure to CPT, a tumor suppressor p53 is activated, and in turn stimulates p21, thereby inducing cell growth arrest in order to have time to repair the damaged DNA. If DNA damage is severe, p53 stimulates a proapoptotic Bcl-2 family member Bax, causing impaired cells undergoing apoptosis. Studies have demonstrated that p53-induced stimulation of Bax plays a significant role in the cellular response to a variety of chemotherapeutic agents (McCurrach et al. 1997; Zhang et al. 2000) . Thus, we next examined whether hypoxia modulates pro-apoptotic Bax in response to CPT in HCT116 cells under the same experimental conditions explored. As demonstrated in Figure 3A , in normoxic condition, Bax accumulation was induced by CPT treatment, leading to apoptosis, suggesting that CPT has a cytotoxic effect in a p53-dependent manner. However, Bax level was significantly down-shifted in CPT-treated cells, when pre-exposed to hypoxia, in spite of stimulated p53 and p21. The level of Bax expression was about 0.37-fold lower without CPT (43% band densitometry value) than with CPT (16% band densitometry value) under hypoxic condition (Fig. 3B) . Studies have shown that p21 attenuates apoptotic effect mediated by DNA damaging agents in HCT116 cells (Waldman et al. 1996; Bunz et al. 1999) . In this regard, it is important to note that p21 was highly expressed under both hypoxia and normoxia when treated with CPT, Fig. 3 . Western blot analysis showing the protein levels of p53, p21, and Bax in HCT116 cells exposed to hypoxia and CPT. (A) HCT116 cells pre-exposed to hypoxia or normoxia for 24 h were incubated with CPT (1 µM) for an additional 6 h, and then processed and subjected to Western blotting to determine the expression levels of p53, p21, and Bax. As a control for equal loading of the samples, the β-actin levels were used. (B) The band densitometry analysis for quantifying Western blot data. The value for Bax expression level in response to CPT under normoxia was set as 100%. The band densitometry analysis was performed with Image J software. The experiment was repeated three times. The data represent mean ± S.E.M. * p < 0.05, compared to w/o CPT under normoxia and hypoxia, respectively. but hypoxic cells only escaped from apoptosis induced by CPT. Our results suggest that the protective effect of p21 on apoptotic cell death may not be related with hypoxia inhibition of CPT-induced apoptosis in HCT116 cells under our experimental settings. Bax expression was clearly and significantly down-regulated in CPTtreated cells under hypoxic condition. Our data indicate that hypoxia regulates CPT-induced apoptosis by down-regulating Bax expression, thereby rendering tumor cells resistance to cell death. Also, our data suggest that there may be a mechanism bypassing p53, which down-regulates Bax expression under hypoxic condition.
Discussion
As well-known, the mitochondrial events regulate the apoptotic cell death via the balance of pro-and antiapoptotic Bcl-2 family members (Scorrano & Korsmeyer 2003) . Among these Bcl-2 members, Bax plays a pivotal role in apoptosis triggered by various death stimuli, such as UV, radiation, chemotherapeutic agents and death ligands including TRAIL (Deng et al. 2002; Theodorakis et al. 2002) . Studies have demonstrated that Bax-deficiency renders HCT116 cells completely resistant to TRAIL-induced apoptosis (LeBlanc et al. 2002; Ravi & Bedi 2002) . In our previous study, we showed that hypoxia inhibits TRAIL-induced apoptosis by blocking Bax translocation to the mitochondria without decreasing the levels of Bax protein (Kim et al. 2004) . Considering Bax-deficiency is crucial for the resistance to tumoricidal activity, inhibition of Bax translocation to the mitochondria exhibited a functional similarity to the Bax-deficient state.
In this study, our aim was to determine whether hypoxia renders colon cancer cells resistant to CPT, and if so, the molecular mechanism by which hypoxia suppresses CPT-induced apoptosis in HCT116 cells. Here, we demonstrate that a down-regulation of Bax is critically important for hypoxia to block CPT-induced apoptosis. Our data are in good agreement with the previous findings that Bax deficiency or decreased Bax levels are associated with reduced susceptibility to tumoricidal effect of death inducers. Thus, modulation of Bax appears to be a key mechanism for hypoxia to attenuate apoptotic activity of death inducers.
In our study, hypoxia affected CPT-induced apoptosis in HCT116 cells, but not in MCF-7 and A549 cells. Interestingly, Said et al (2009) reported that the levels of hypoxia-inducible factor 1, a transcription factor that is a critical mediator of the cellular response to hypoxia, are markedly higher in HCT116 cells than in A549 cells after 24-hour hypoxia exposure. Considering this, difference in hypoxia-inducible factor 1 protein level may be responsible for the cell-type specific feature related to tumorigenic potential observed in current study. Hypoxia differentially modulates gene expression and protein levels in solid tumors, thus influencing both angiogenesis and tumorigenesis. Previous study has also demonstrated that hypoxia-responsive genes are differentially expressed in different cell types (Chi et al. 2006) . So far, it is not clear how different cell types respond to hypoxia. The detailed mechanism by which hypoxia regulates apoptosis in cancer cells is poorly understood, thus remaining to be elucidated.
From our previous and current findings, we propose mechanisms by which hypoxia inhibits apoptosis induced by TRAIL or CPT (Fig. 4) . In response to a death ligand TRAIL, procaspase-8 is cleaved and activated. This activated form of caspase-8, an initiator caspase, in turn induces the cleavage of Bid to truncated Bid (tBid), which leads to the activation of the intrinsic mitochondria-dependent apoptotic pathway. Also, caspase-8 is able to directly stimulate caspase-3, an effector caspase, so called the extrinsic mitochondriaindependent apoptotic pathway. With the translocation of tBid to the mitochondria, cytosolic inactive Bax is subsequently activated and translocates to the mitochondria, which is a critical step in apoptosis. And then, through the mitochondria-caspase-9 pathway, the terminal effector caspase-3 is activated, thereby causing rapid cell destruction. In case of CPT-induced apop- tosis, it is well-known that the HCT116 colon cancer cells treated with CPT undergo p53-dependent apoptosis. In normal cells, p53 is expressed at extremely low levels. Upon exposure to CPT, tumor suppressor p53 is increased and activated, and in turn stimulates p21, concomitantly inducing cell growth arrest in order to have enough time to repair the damaged DNA. If DNA damage is excessive, p53 stimulates proapoptotic Bax, which causes impaired cells undergoing apoptosis. As shown here, however, hypoxia rendered HCT116 cells resistant to CPT-induced apoptosis by down-regulating Bax, without affecting CPT-induced up-regulation of p53 and p21. Our findings suggest that p53 activation may not be necessary for hypoxia inhibition of CPT-induced Bax loss, and there may be an unknown mechanism for hypoxia to regulate the functionality of p53, which is associated with induction of Bax. Considering that enhanced proteasomal degradation of Bax is associated with cancer cell survival, protein stability is one of key regulatory mechanisms in controlling apoptosis. Thus, it is possibly assumed that ubiquitin-proteasome pathway may be responsible for Bax instability under hypoxia. In nonapoptotic cells, the hydrophobic C-terminal tail of Bax binds to and masks the BH-3 domain (Suzuki et al. 2000) . This structure is more susceptible to proteasomal degradation. Upon apoptotic stimuli, Bax undergoes a conformational change, resulting in the exposure of the masked BH-3 domain, followed by its translocation to the mitochondria. Studies have demonstrated that proteasome inhibitors, such as MG115, MG132, LLnV, etc., induce apoptosis by stabilizing Bax protein and preventing proteasomal degradation of Bax protein (Li & Dou 2000; Agrawal et al. 2008) . Given that enhanced proteasomal degradation of Bax protein is a common feature of Bax instability, the ubiquitinated forms of Bax protein should increase in response to the deprivation of proteasome activity. Indeed, Li & Dou (2000) have demonstrated that reduced proteasome activity resulted in the accumulation of ubiquitinated Bax, without changing mRNA expression of Bax. Along this line, our results showing that hypoxia inhibits CPT-induced apoptosis by Bax loss suggest that hypoxia may be involved in the regulation of Bax stability through ubiquitin-proteasome pathway, regardless of p53 status. But, little is known on how hypoxia modulates Bax instability in p53-indepent manner. To test this hypothesis, more detailed studies on hypoxia-mediated down-regulation of Bax are under way. Cuisnier et al. (2003) reported that hypoxia rendered human squamous cell carcinoma resistant to γ-irradiation-induced apoptosis. They have demonstrated that the level of Bax protein significantly decreased in hypoxic cells, following treatment with hypoxia and irradiation. In that study, it has been also shown that normoxic cells exhibited a huge increase in reactive oxygen species (ROS) production compared to cells irradiated identically under hypoxic condition, indicating that hypoxia inhibits radiation-induced apoptosis by preventing ROS production. There have been evidences that ROS induces Bax up-regulation, and Bcl-2 down-regulation, thus leading to higher Bax/Bcl-2 ratio (Hockenbery et al. 1993; Kumar & Jugdutt 2003) . Also, it has been known that Bcl-2 overexpression protects cells from apoptosis mediated by ROS. Interestingly, Bcl-2 protein has been considered to act as an antioxidant that may regulate intracellular ROS (Hockenbery et al. 1993) . In this regard, it is also possibly assumed that lower Bax/Bcl-2 ratio mediated by hypoxia may contribute to lower levels of ROS expression in cancer cells, thereby allowing tumor cells to acquire resistance to apoptosis.
Based on our results and others, Bax appears to be the pivotal factor in regulating the inhibitory effect of hypoxia on apoptosis in response to TRAIL and CPT by blocking Bax translocation and downregulating Bax, respectively. Given that Bax-deficiency by hypoxia may be a mechanism by which tumor cells survive against tumor therapies and an anti-tumor immunity that induces tumor apoptosis, our data suggest that a reversal of the decreased Bax expression levels might be important, at least, for CPT to increase therapeutic potential of tumor therapies in hypoxic conditions. Although our study uncovers a mechanism attenuating tumor cell apoptosis under a hypoxic condition, the detailed mechanism, underlying inhibited Bax translocation, p53-loss-of-function in Bax induction, remains to be elucidated. Knowledge of the regulation mechanism of Bax under hypoxia may provide an effective tool for overcoming resistance of hypoxic tumor cells to the therapeutic agents.
